Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (IC...
09 Mai 2017 - 2:00PM
Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced
that clinical results from the Phase 2 study of cerdulatinib in
patients with relapsed/refractory b-cell malignancies will be
shared in an oral presentation at the International Conference on
Malignant Lymphoma (ICML), which is taking place from June 14-17 in
Lugano, Switzerland.
Cerdulatinib is an investigational oral, dual
SYK/JAK kinase inhibitor in development to treat patients with
resistant or relapsed hematologic cancers. Cerdulatinib inhibits
two key signaling pathways that promote cancer cell growth in
certain hematologic malignancies.Details regarding the oral
presentation follow.
Oral Presentation Details:
- Abstract Title: The Dual SYK/JAK Inhibitor
Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study
in Patients with Relapsed/Refractory B-Cell Malignancies
- Presenting Author: P.A. Hamlin, Memorial Sloan
Kettering Cancer Center
- Presentation Date and Time: June 15, 2017 at
4:40 p.m. CEST
- Location: Room A, Cinema Corso and Aula Magna
(Lugano University)
About Portola Pharmaceuticals,
Inc. Portola Pharmaceuticals is a biopharmaceutical
company developing product candidates that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company is advancing three programs, including betrixaban, an
oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a
recombinant protein designed to reverse the anticoagulant effect in
patients treated with an oral or injectable Factor Xa inhibitor;
and cerdulatinib, a SYK/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective SYK inhibitors for inflammatory conditions.
For more information, visit http://www.portola.com and follow
the Company on Twitter @Portola_Pharma.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
Pure Communications
jnormart@purecommunications.com
415.946.1087
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur